Ngamprasertwong Pornswan, Dong Min, Niu Jing, Venkatasubramanian Raja, Vinks Alexander A, Sadhasivam Senthilkumar
Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States of America.
Division of Clinical Pharmacology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States of America.
PLoS One. 2016 Jan 11;11(1):e0146563. doi: 10.1371/journal.pone.0146563. eCollection 2016.
Measuring fetal drug concentrations is extremely difficult in humans. We conducted a study in pregnant sheep to simultaneously describe maternal and fetal concentrations of propofol, a common intravenous anesthetic agent used in humans. Compared to inhalational anesthesia, propofol supplemented anesthesia lowered the dose of desflurane required to provide adequate uterine relaxation during open fetal surgery. This resulted in better intraoperative fetal cardiac outcome. This study describes maternal and fetal propofol pharmacokinetics (PK) using a chronically instrumented maternal-fetal sheep model.
Fetal and maternal blood samples were simultaneously collected from eight mid-gestational pregnant ewes during general anesthesia with propofol, remifentanil and desflurane. Nonlinear mixed-effects modeling was performed by using NONMEM software. Total body weight, gestational age and hemodynamic parameters were tested in the covariate analysis. The final model was validated by bootstrapping and visual predictive check.
A total of 160 propofol samples were collected. A 2-compartment maternal PK model with a third fetal compartment appropriately described the data. Mean population parameter estimates for maternal propofol clearance and central volume of distribution were 4.17 L/min and 37.7 L, respectively, in a typical ewe with a median heart rate of 135 beats/min. Increase in maternal heart rate significantly correlated with increase in propofol clearance. The estimated population maternal-fetal inter-compartment clearance was 0.0138 L/min and the volume of distribution of propofol in the fetus was 0.144 L. Fetal propofol clearance was found to be almost negligible compared to maternal clearance and could not be robustly estimated.
For the first time, a maternal-fetal PK model of propofol in pregnant ewes was successfully developed. This study narrows the gap in our knowledge in maternal-fetal PK model in human. Our study confirms that maternal heart rate has an important influence on the pharmacokinetics of propofol during pregnancy. Much lower propofol concentration in the fetus compared to maternal concentrations explain limited placental transfer in in-vivo paired model, and less direct fetal cardiac depression we observed earlier with propofol supplemented inhalational anesthesia compared to higher dose inhalational anesthesia in humans and sheep.
在人类中测量胎儿药物浓度极其困难。我们在怀孕绵羊身上进行了一项研究,以同时描述丙泊酚(一种在人类中常用的静脉麻醉剂)在母体和胎儿体内的浓度。与吸入麻醉相比,丙泊酚辅助麻醉降低了在开放性胎儿手术期间提供足够子宫松弛所需的地氟醚剂量。这导致了更好的术中胎儿心脏结局。本研究使用长期植入仪器的母胎绵羊模型描述了母体和胎儿的丙泊酚药代动力学(PK)。
在丙泊酚、瑞芬太尼和地氟醚全身麻醉期间,从八只妊娠中期的怀孕母羊中同时采集胎儿和母体血样。使用NONMEM软件进行非线性混合效应建模。在协变量分析中测试了总体重、胎龄和血流动力学参数。通过自举法和视觉预测检查对最终模型进行验证。
共采集了160份丙泊酚样本。一个具有第三个胎儿房室的二房室母体PK模型恰当地描述了数据。在一只典型的母羊中,母体丙泊酚清除率和中央分布容积的平均总体参数估计值分别为4.17 L/分钟和37.7 L,中位心率为135次/分钟。母体心率的增加与丙泊酚清除率的增加显著相关。估计的母体-胎儿房室间清除率为0.0138 L/分钟,丙泊酚在胎儿体内的分布容积为0.144 L。与母体清除率相比,胎儿丙泊酚清除率几乎可以忽略不计,且无法可靠估计。
首次成功建立了怀孕母羊中丙泊酚的母胎PK模型。本研究缩小了我们在人类母胎PK模型方面的知识差距。我们的研究证实,母体心率对孕期丙泊酚的药代动力学有重要影响。与母体浓度相比,胎儿体内丙泊酚浓度低得多,这解释了体内配对模型中有限的胎盘转运,以及与人类和绵羊中高剂量吸入麻醉相比,我们早期观察到的丙泊酚辅助吸入麻醉对胎儿心脏的直接抑制作用较小。